parkinson's and glp 1 GLP-1 Agonists: A New Frontier in Treatment? GLP-1a: Going beyond Traditional Use

Name: parkinson's and glp 1 GLP-1 Agonists: A New Frontier in Treatment? GLP-1a: Going beyond Traditional Use
Brand: skorenge.com
SKU: 65737517649
Price: 23.87 USD
Availability: InStock
Rating: 4.5535000000000005 (30 reviews)

SKU: 65737517649

4.6

EUR23.87 EUR56.87

Pay in 4 interest-free payments of $5.97 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

GLP 1a: Going beyond Traditional Use GLP 1 and Parkinson's Disease: Research, Benefits and Risks Fella Health New studies on GLP 1 for slowing Parkinson's disease progression The glucagon like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action ScienceDirect Some epidemiologic studies have suggested that the risk of Parkinson's disease is increased among persons with type 2 #Diabetes, with the risk potentially attenuated in those taking glucagon like peptide 1 (GLP 1) receptor agonists.

Store: skorenge.com · Domain: skorenge.com

Description

In SOUL, composite HF endpoints were analysed as a secondary outcome, with oral semaglutide resulting in a non-significant reduction in HF events

doi: 10.1016/j.cell.2020.08.003 [DOI] [PMC free article] [PubMed] [Google Scholar] Drucker D